CASI Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
CASI Pharmaceuticals has a total shareholder equity of $62.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $88.4M and $26.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$44.29m |
Equity | US$62.22m |
Total liabilities | US$26.17m |
Total assets | US$88.40m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: YZ3's short term assets ($66.6M) exceed its short term liabilities ($14.0M).
Long Term Liabilities: YZ3's short term assets ($66.6M) exceed its long term liabilities ($12.1M).
Debt to Equity History and Analysis
Debt Level: YZ3 is debt free.
Reducing Debt: YZ3 has no debt compared to 5 years ago when its debt to equity ratio was 2.2%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: YZ3 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: YZ3 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.8% each year